Aktis Oncology rallies $72m Series A

Aktis Oncology, a biotechnology company focused on treating solid tumor cancers, has secured $72 million in Series A financing.

18 March 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles